The approval is based on a Phase III trial showing that Tecentriq significantly improved survival in patients with metastatic non-small cell lung cancer.
A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.
IMvigor130 data suggests atezolizumab plus chemotherapy delays progression in urothelial carcinoma, with potential survival benefit seen in PD-L1 subgroup treated with monotherapy.
